The global castration-resistant prostate cancer therapeutics market is expanding as advances in oncology continue to provide additional treatment options for patients with advanced disease. The therapeutic landscape includes androgen receptor pathway inhibitors, chemotherapy, radiopharmaceuticals, PARP inhibitors for selected genetic profiles, and immunotherapy. Increasing focus on precision...